MPEP (drug)

MPEP
Clinical data
Other names	1-(α-Methylphenethyl)pyrrolidine; α-Methylphenethylpyrrolidine; α-Methyl-PEP; 1-(1-Methyl-2-phenylethyl)pyrrolidine
Drug class	Stimulant
ATC code	None;
Identifiers
	IUPAC name 1-(1-phenylpropan-2-yl)pyrrolidine;
PubChem CID	53665923;
ChemSpider	57577614;
Chemical and physical data
Formula	C13H19N
Molar mass	189.302 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(CC1=CC=CC=C1)N2CCCC2;
	InChI InChI=1S/C13H19N/c1-12(14-9-5-6-10-14)11-13-7-3-2-4-8-13/h2-4,7-8,12H,5-6,9-11H2,1H3; Key:AWNZMWZMSDWFCV-UHFFFAOYSA-N;

MPEP, also known as 1-(α-methylphenethyl)pyrrolidine, is a stimulant drug of the phenethylamine, amphetamine, and phenylethylpyrrolidine families. It is the α-methyl derivative of phenylethylpyrrolidine (PEP). Notable derivatives of MPEP include prolintane (the α-propyl homologue), α-PPP (the β-keto or cathinone derivative), α-PVP (the β-keto and α-propyl homologue), pyrovalerone (4-methyl-α-PVP), and MDPV (3,4-methylenedioxy-α-PVP), among others. These compounds are known to act as norepinephrine–dopamine reuptake inhibitors (NDRIs) to produce their stimulant effects. MPEP was first described in the scientific literature by R. V. Heinzelman and B. D. Aspergren by 1953.